AMG 509 (Xaluritamig) updates about t... - Fight Prostate Ca...

Fight Prostate Cancer

3,027 members1,497 posts

AMG 509 (Xaluritamig) updates about the clinical trial

Maxone73 profile image
4 Replies

A Phase 3 trial is recruiting 675 patients to be randomized to Xaluritamig versus cabazitaxel or an AR switch, aiming to establish its superiority as a second-line treatment.

Xaluritamig is a STEAP1-targeted T-cell engager being developed for metastatic castration-resistant prostate cancer (mCRPC). It binds to STEAP1 on cancer cells and CD3 on T-cells, facilitating the targeted killing of prostate cancer cells. STEAP1 is highly expressed in prostate cancer and minimally expressed in normal tissues, which enhances precision.

The most common side effects are Cytokine Release Syndrome (CRS), which occurred in 75% of patients, and musculoskeletal inflammatory events seen in 76% of patients. These side effects are generally manageable with steroids or tocilizumab, or by holding doses and administering steroids or tocilizumab. First-dose administration requires 24-hour hospital monitoring.

From the previous phase 1/2 trials:

- Efficacy results include 36-60% of patients achieving a ≥50% PSA reduction (PSA 50), and 20-30% achieving ≥90% reductions (PSA 90).

- Objective responses ranged from 14-28%, with 20% of patients with liver metastases showing a response.

- The median radiographic progression-free survival (rPFS) was 7.7 months, extending to 8.3 months at doses of 0.75 mg or higher, and median overall survival (OS) reached 17.7 months.

Remember that we are talking about a heavily pretreated population.

prostatewarriors.com/2024/1...

Written by
Maxone73 profile image
Maxone73
To view profiles and participate in discussions please or .
Read more about...
4 Replies
Maxone73 profile image
Maxone73

As a matter of fact, I thought about you

Maxone73 profile image
Maxone73

Lately you sounded more worried than usual...so when I get something promising for advanced stages (or something that involves ATM) I think you might find it useful.

Maxone73 profile image
Maxone73

Finger crossed for the vacation!

Maxone73 profile image
Maxone73

Yup, one of my friend is in the study group that discovered that LIG1 knockdown should make tumors more sensitive to parp inhibitors

Not what you're looking for?

You may also like...

Phase 3 ended: ECLIPSE trial of 177Lu-PSMA-I&T

A phase 3 clinical trial called ECLIPSE has shown that 177Lu-PSMA-I&T significantly extends the...
Maxone73 profile image

Pick of the Month: JANX007, why?

Ok, I have been reviewing my notes and I must say that, even if it's still a phase 1 trial, I like...
Maxone73 profile image

Phase 1 ACCEL trial recruiting: AC-225-PSMA-62 for OLIGOMETASTATIC HSPC and mCRPC

I am not oligometastatic, dammit! But this could really be something worth trying! It is, at least...
Maxone73 profile image

ASCO Gu 2025: real world data confirms that undetectable PSA nadir is a strong predictor of outcomes

Real world seems to confirm clinical trial data in this case! A real-world study from the IRONMAN...
Maxone73 profile image

Phase 3 trial for localized prostate cancer should be completed in December 2024

CAN-2409 is an immunotherapy drug currently in a Phase 3 clinical trial (PrTK03, NCT01436968) for...
Maxone73 profile image